The forecast for obstructive airway diseases medicine sales in Canada shows a steady increase from $1.71 billion in 2024 to $1.89 billion in 2028. Year-on-year, the growth is approximately 2.34% to 2.22%, reflecting a consistent upward trajectory and pointing to a compound annual growth rate (CAGR) of about 2.5% over the five-year period. Notably, in 2023, the sales stood lower than $1.71 billion.

Future trends to watch for include:

The emergence and integration of new therapies and technologies.
Potential shifts in healthcare policies impacting medication pricing and availability.
Demographic changes influencing patient demand, particularly an aging population.
Increased awareness and diagnostics of obstructive airway conditions.